Raumedic, the development and system supplier for the medical and pharmaceutical industry, is restructuring its business units
Over the last two years Raumedic said it has invested a lot in the expansion and development of its locations in Europe and North America.
A polymer processor specialising in medical engineering and pharmaceuticals is expected to produce efficient and flexible structures.
Raumedic said that this is especially important when it comes to realising customised products by means of extrusion, injection molding and assembly, which is why the company is establishing a new organisation and structure.
The company’s original three business units will become two. Operations concerning extruded tubing will continue to be coordinated within the tubing business unit but injection molding components and their subsequent processing into modules and systems will be housed within the systems business unit.
Raumedic said that this will help to ensure that all expertise concerning the development and production of complex system products is centralised in one unit.
Martin Bayer, sole managing director of Raumedic, said: “This new structure guarantees that the technology, quality and service that we as a polymer specialist for the medical engineering and pharmaceutical industry offer, will also in future be highly qualified and quickly available for our customers and their product ideas.”
Raumedic said that these technologies include, among others things, micro and multi-component injection molding, insertion molding, fully automated assembly facilities, extrusion of tubing (also in the micro-range) and film blowing.
The raw materials employed in the production of these technologies include nearly all thermoplastics as well as silicone.